Related Experiment Video
Updated: Jan 15, 2026

In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments
Published on: October 25, 2016
Tolerogenic probiotics and gut-brain axis: targeting pain receptors in neuroimmune disorders
Maryam Ahmadi-Khorram1,2, Alireza Hatami1,2, Fatemeh Forouzanfar3,4
1Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:
Tolerogenic probiotics, including Lactobacillus and Bifidobacterium species, offer significant therapeutic potential for neuroimmune disorders by modulating the gut-brain axis to promote immune tolerance and reduce inflammation. These probiotics influence key cell types, such as enteroendocrine cells (EECs), intestinal epithelial cells (IECs), and enteric glial cells (EGCs), enhancing gut barrier integrity and regulating hormone secretion (e.g. GLP-1, serotonin). They also modulate pain receptors, including transient receptor potential vanilloid 1 (TRPV1), cannabinoid (CB1, CB2), opioid (mu, kappa), and serotonin (5-HT) receptors, to alleviate visceral and neuropathic pain hypersensitivity. Despite promising preclinical evidence, challenges such as inconsistent dosing protocols, strain-specific efficacy, and limited large-scale clinical trials hinder clinical translation. This review synthesizes the mechanisms by which tolerogenic probiotics target the gut-brain axis and pain receptors, highlighting research gaps and proposing directions for personalized therapies and standardized clinical approaches.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Analgesia and Pain Management
Nociception
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Physiology of Enteric Nervous System and Gut Health
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

